Letter to Shareholders from CEO Dr. Ryan Saadi
Rhea-AI Summary
Tevogen (Nasdaq: TVGN) CEO Dr. Ryan Saadi provided a shareholder letter (March 6, 2026) outlining strategic acquisition evaluations to complement its immunotherapy and AI platforms. The company said potential targets, if acquired as subsidiaries, may generate aggregate annual revenues in excess of $50 million, subject to due diligence and definitive agreements.
Tevogen emphasized disciplined capital allocation, operational efficiency, and a focus on building a sustainable, revenue-generating healthcare enterprise while pursuing these strategic initiatives.
Positive
- None.
Negative
- None.
News Market Reaction – TVGN
On the day this news was published, TVGN declined 5.74%, reflecting a notable negative market reaction. Argus tracked a peak move of +58.5% during that session. Argus tracked a trough of -8.4% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $43.37M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TVGN fell 16.7% with elevated volume, while no peers appeared in the momentum scanner and peer price moves from the sector list were more moderate. With 0 peers flagged in momentum and no same-day peer headlines, trading pressure appears stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Generics LOI | Positive | -16.7% | LOI to evaluate acquiring Apozeal generics platform with 11 FDA-approved ANDAs. |
| Mar 04 | Reverse stock split | Neutral | -24.8% | 50-for-1 reverse split to address Nasdaq minimum bid price requirement. |
| Feb 27 | CRO acquisition LOI | Positive | -8.7% | LOI to evaluate acquiring global CRO to expand clinical development services. |
| Feb 26 | Sciometrix LOI update | Positive | -8.7% | Updated LOI for Sciometrix/Clinicus digital care platform to support revenue shift. |
| Feb 26 | Sciometrix LOI | Positive | +0.1% | Initial LOI for Sciometrix and Clinicus to enhance data and value-based care. |
Recent strategic and capital-structure announcements, including multiple LOIs and a reverse split, were followed by predominantly negative price reactions, suggesting a pattern of selling into corporate updates.
Over the last few weeks, Tevogen issued several strategic updates focused on acquisitions and capital structure. On Feb 26–27, 2026, it announced LOIs for Sciometrix, a CRO, and related digital platforms, aiming to become a revenue-generating healthcare enterprise; shares reacted negatively around -8.71%. A 50-for-1 reverse split announced on Mar 4, 2026 saw a -24.83% move. A further generics-focused LOI on Mar 5, 2026 coincided with a -16.7% move. Today’s shareholder letter reiterates this acquisition-driven, cash-flow-focused strategy against that backdrop.
Market Pulse Summary
The stock moved -5.7% in the session following this news. A negative reaction despite a growth-focused shareholder letter fits the recent pattern in which Tevogen’s acquisition LOIs and reverse split announcements around Feb–Mar 2026 were followed by price declines. The update reiterated potential deals with aggregate revenues above $50 million, but none are definitive and remain subject to due diligence and agreements. Investors may have focused on execution uncertainty and the company’s need to stabilize its financial foundation despite the long-term strategic framing.
Key Terms
immunotherapy medical
artificial intelligence technical
subsidiaries financial
return on invested capital financial
capital allocation financial
AI-generated analysis. Not financial advice.
WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN).
Dear Shareholders,
As we continue executing on Tevogen’s long-term strategy to evolve into a sustainable, revenue-generating healthcare enterprise, I would like to provide an update regarding our ongoing strategic initiatives.
Over the past several months, we have been actively evaluating potential acquisitions designed to complement our existing immunotherapy and artificial intelligence platforms. If consummated, these transactions are expected to operate as subsidiaries of Tevogen resulting in positive cash flow generation and a return on invested capital over time.
Based on preliminary evaluations, the combined entities under consideration may generate aggregate annual revenues in excess of
Tevogen was built on the belief that innovation and affordability are not mutually exclusive. As we expand, we remain committed to disciplined capital allocation, operational efficiency, and long-term shareholder value creation.
We appreciate your continued trust and support as we pursue strategic initiatives intended to strengthen Tevogen’s financial foundation while advancing our mission of developing accessible immunotherapies.
Sincerely,
Dr. Ryan Saadi
Founder & Chief Executive Officer
Tevogen
About Tevogen
Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.
Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.
Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.
Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: the potential transactions and the potential benefits of the transactions; Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: risks inherent in diligence and negotiation of the proposed transactions; the risk that the transactions may not be consummated on favorable terms or at all; the risk that the expected benefits of the transactions may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
